Korman Tyler Paz has filed an amendment to a previous ownership report, clarifying details about his stock holdings in ExoZymes Inc. This amendment is significant as it corrects an earlier filing that inaccurately reported the conversion of restricted stock units into common stock.
The filing, dated October 21, 2026, addresses a mistake in a report submitted on August 25, 2026. The earlier report indicated that Paz converted 32,964 restricted stock units into shares, which did not occur. The amendment ensures that ownership records reflect the accurate status of his holdings.
Background
Korman Tyler Paz is currently the Chief Scientific Officer at ExoZymes Inc., a company specializing in biological products, specifically in the realm of life sciences. The company, incorporated in Nevada, has been active in the market with its focus on innovative biological solutions. Recent filings include the amendment on October 21 and earlier reports throughout 2026.
What the Filing Says
The amendment states, "This Amendment is being filed to correct the Form 4 filed August 25, 2026, which reported the conversion of 32,964 restricted stock units into 32,964 shares of common stock on August 19, 2026. That transaction was reported in error. The conversion did not occur and no shares were issued." This clarification is crucial for maintaining accurate public records.
Impact
This amendment may affect stakeholders, including investors and employees of ExoZymes Inc., by providing a clearer picture of ownership and stock management. Transparency in stock ownership is essential for maintaining investor confidence, especially in the competitive biological products industry.
What's Next
The filing does not say what happens next.